Press Resease

Melanoma Drugs Market - Global Industry Analysis

Melanoma Drugs Market By Therapy (Chemotherapy, Immunotherapy And Targeted Therapy) And Region: Global Industry Perspective, Comprehensive Analysis, Size, Share, Growth, Segment, Trends And Forecast, 2020 – 2028

Published Date: 29-Jul-2021 Category: Pharmaceutical Report Format : PDF Pages: 140 Report Code: ZMR-889 Status : Published

The Global Melanoma Drugs Market was accounted for USD 3.8 Billion in 2020 and is expected to reach USD 7.4 Billion by 2028, growing at a CAGR of around 8.1% between 2021 and 2028.

Description

Market Overview     

The Global Melanoma Drugs Market was accounted for USD 3.8 Billion in 2020 and is expected to reach USD 7.4 Billion by 2028, growing at a CAGR of around 8.1% between 2021 and 2028.    

The global melanoma drugs market is majorly boosted by increasing cases of target disease everywhere on the planet. A number of the main boosting factors are combination treatment with better survival & lesser side effects and therefore the development of novel agents. On the opposite hand, the high cost of clinical trials and combination therapies paired with possible side effects or adverse effects are the first limitations that will hinder the event of the melanoma drugs market.

Nevertheless increasing aim on customized medicine paired alongside huge spending in anti-melanoma drugs research everywhere the planet are expected to reveal the new growth opportunities for the melanoma drugs market within the years to return. For instance, in December 2017, the FDA approved the anti-PD1 antibody, named nivolumab for the adjuvant therapy of individuals affected by melanoma. Nivolumab was earlier approved for the treatment of individuals affected by metastatic or unresectable melanoma. This approval has lent a hand to the event o the melanoma drugs market.

Global Melanoma Drugs Market Size

COVID-19 Impact Analysis

Currently, the demand for Melanoma Drugs is on the increase during the COVID-19 pandemic. However, this requirement is probably going to be hindered owing to reductions within the budgets of electronics companies and individuals due to partial lockdowns imposed worldwide. The lockdowns have caused severe losses to the worldwide industry players and placed restrictions on public gatherings at theatres, concerts, international events, and music festivals, which is clogging the market growth. Furthermore, the market is indicating a big recovery rate, mainly attributed to the remote working policies adopted by many industry players to stop the spread of COVID-19 at workplaces. The industry is, however, expected to face challenges within the future due to the consequences of COVID-19.

The global Melanoma Drugs market has witnessed a slight decline in the sales for short term to the lockdown enforcement placed by governments to contain COVID spreading. The restrictions imposed by various nations to contain COVID had stopped the production resulting in disruption across the whole supply chain. However, the global markets are slowly opening to their full potential, and theirs a surge in demand. Rising support from governments and several companies can help in the fight against this disease. Overall, almost every sector is anticipated to be impacted by the pandemic.

The significant decrease in the global Melanoma Drugs market size in 2020 is estimated based on the COVID-19 outbreak and its negative impact on the economies and industries across the globe. Various scenarios have been analyzed based on inputs from various secondary sources and the current data available about the situation.

Growth Factors

The prevalence of skin allergies, melanoma, and other skin cancers in developing countries is high, which is a chance for drug companies to realize a bigger share in these regions. Increasing demand for cost-efficient therapeutics in developing regions, like Asia Pacific and Middle East & Africa, has encouraged major players to develop cheaper and effective drugs. These factors are expected to fuel the expansion of the general market within the coming years.

Report Scope:

Report Attribute Details
Base Year 2020
Historic Years 2016 - 2020
Forecast Years 2021 - 2028
Segments Covered By Product Type, By Application, and By End Use
Forecast Units Value (USD Billion), and Volume (Units)
Quantitative Units Revenue in USD million/billion and CAGR from 2021 to 2028
Regions Covered North America, Europe, Asia Pacific, Latin America, and Middle East & Africa, and Rest of World
Countries Covered U.S., Canada, Mexico, U.K., Germany, France, Italy, Spain, China, India, Japan, South Korea, Brazil, Argentina, GCC Countries, and South Africa, among others
Number of Companies Covered 10 companies with scope for including additional 15 companies upon request
Report Coverage Market growth drivers, restraints, opportunities, Porter’s five forces analysis, PEST analysis, value chain analysis, regulatory landscape, market attractiveness analysis by segments and region, company market share analysis, and COVID-19 impact analysis.
Customization Scope Avail customized purchase options to meet your exact research needs.

Segment Analysis Preview   

The melanoma drugs market is divided based on various therapeutic sections comprising immunotherapy, chemotherapy, and targeted therapy. FDA-accepted immunotherapy agents such as nivolumab and pembrolizumab are understudies of major players. Thus immunotherapy section is likely to develop at the quickest rate in the melanoma drugs market soon.

Regional Segment Analysis Preview   

Regionally, North America is likely to remain the dominant region in melanoma drugs n the years to come. The requirement for melanoma drugs was uppermost in North America particularly in the U.S. Hence, the Asia Pacific is likely to be the reasonable-developing area during the forecast period in the melanoma drugs market. In addition to this, Latin America and the Middle East & Africa are also likely to exhibit moderate development in the years to come for the melanoma drugs market.

Global Melanoma Drugs Market Share

Key Market Players & Competitive Landscape

The key companies operating in the Melanoma Drugs market include Bristol-Myers Squibb, Amgen, Genentech Inc., Hoffmann-La Roche Ltd, Novartis International AG., Janssen Biotech, Inc., Sanofi, Pfizer, Teva Pharmaceuticals, and Takeda Pharmaceutical Company Limited among others. These players are claimed to bolster the global melanoma drugs market in the years to come.

Global Melanoma Drugs Market Regional Analysis

The global Melanoma Drugs Market is segmented as follows:

By Therapy

  • Chemotherapy
  • Immunotherapy
  • Targeted Therapy

By Region

  • North America
    • The U.S.
    • Canada
  • Europe
    • France
    • The UK
    • Spain
    • Germany
    • Italy
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Southeast Asia
    • Rest of Asia Pacific
  • Latin America
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East & Africa
    • GCC
    • South Africa
    • Rest of Middle East & Africa

 

 

 

Table Of Content

  • Chapter No. 1: Introduction
    • 1.1. Report Description
      • 1.1.1. Purpose of the Report
      • 1.1.2. USP & Key Offerings
    • 1.2. Key Benefits for Stakehulders
    • 1.3. Target Audience
    • 1.4. Report Scope
  • Chapter No. 2: Executive Summary
    • 2.1. Key Findings
      • 2.1.1. Top Investment Pockets
        • 2.1.1.1. Market Attractiveness Analysis, By Therapy
        • 2.1.1.2. Market Attractiveness Analysis, By Region
    • 2.2. Market Snapshot
    • 2.3. Global Melanoma Drugs Market , 2016 – 2028 (USD Billion)
    • 2.4. Insights from Primary Respondents
  • Chapter No. 3: COVID 19 Impact Analysis
    • 3.1. Impact Assessment of COVID-19 Pandemic, By Region
      • 3.1.1. North America
      • 3.1.2. Europe
      • 3.1.3. Asia Pacific
      • 3.1.4. Latin America
      • 3.1.5. The Middle-East and Africa
    • 3.2. Quarterly Market Revenue and Forecast by Region 2020 & 2021
    • 3.3. Pre COVID-19 Market Revenue, By Region, 2016-2019 (USD Billion)
    • 3.4. Post COVID-19 Market Revenue, By Region, 2020-2028 (USD Billion)
    • 3.5. Key Strategies Undertaken by Companies to Tackle COVID-19
      • 3.5.1. Company Quarterly Revenue Analysis, 2019 & 2020
    • 3.6. Short Term Dynamics
    • 3.7. Long Term Dynamics
  • Chapter No. 4: Melanoma Drugs Market – Service Segment Analysis
    • 4.1. Overview
      • 4.1.1. Market Revenue Share, By Therapy, 2020 & 2028
    • 4.2. Chemotherapy
      • 4.2.1. Market Size and Forecast, By Region (USD Billion)
      • 4.2.2. Comparative Revenue Analysis, By Country, 2020 & 2028
      • 4.2.3. Key Market Trends, Growth Factors, & Opportunities
    • 4.3. Immunotherapy
      • 4.3.1. Market Size and Forecast, By Region (USD Billion)
      • 4.3.2. Comparative Revenue Analysis, By Country, 2020 & 2028
      • 4.3.3. Key Market Trends, Growth Factors, & Opportunities
    • 4.4. Targeted Therapy
      • 4.4.1. Market Size and Forecast, By Region (USD Billion)
      • 4.4.2. Comparative Revenue Analysis, By Country, 2020 & 2028
      • 4.4.3. Key Market Trends, Growth Factors, & Opportunities
  • Chapter No. 5: Melanoma Drugs Market – Region Segment Analysis
    • 5.1. Overview
      • 5.1.1. Global Market Revenue Share, By Region, 2020 & 2028
      • 5.1.2. Global Market Revenue, By Region, 2016 – 2028 (USD Billion)
    • 5.2. North America
      • 5.2.1. North America Market Revenue, By Country, 2016 – 2028 (USD Billion)
      • 5.2.2. North America Market Revenue, By Therapy, 2016 – 2028
      • 5.2.5. U.S.
        • 5.2.5.1. U.S. Market Revenue, By Therapy, 2016 – 2028
      • 5.2.6. Canada
        • 5.2.6.1. Canada Market Revenue, By Therapy, 2016 – 2028
      • 5.2.7. Mexico
        • 5.2.7.1. Mexico Market Revenue, By Therapy, 2016 – 2028
    • 5.3. Europe
      • 5.3.1. Europe Market Revenue, By Country, 2016 – 2028 (USD Billion)
      • 5.3.2. Europe Market Revenue, By Therapy, 2016 – 2028
      • 5.3.5. Germany
        • 5.3.5.1. Germany Market Revenue, By Therapy, 2016 – 2028
      • 5.3.6. France
        • 5.3.6.1. France Market Revenue, By Therapy, 2016 – 2028
      • 5.3.7. U.K.
        • 5.3.7.1. U.K. Market Revenue, By Therapy, 2016 – 2028
      • 5.3.8. Italy
        • 5.3.8.1. Italy Market Revenue, By Therapy, 2016 – 2028
      • 5.3.9. Spain
        • 5.3.9.1. Spain Market Revenue, By Therapy, 2016 – 2028
      • 5.3.10. Rest of Europe
        • 5.3.10.1. Rest of Europe Market Revenue, By Therapy, 2016 – 2028
    • 5.4. Asia Pacific
      • 5.4.1. Asia Pacific Market Revenue, By Country, 2016 – 2028 (USD Billion)
      • 5.4.2. Asia Pacific Market Revenue, By Therapy, 2016 – 2028
      • 5.4.5. China
        • 5.4.5.1. China Market Revenue, By Therapy, 2016 – 2028
      • 5.4.6. Japan
        • 5.4.6.1. Japan Market Revenue, By Therapy, 2016 – 2028
      • 5.4.7. India
        • 5.4.7.1. India Market Revenue, By Therapy, 2016 – 2028
      • 5.4.8. South Korea
        • 5.4.8.1. South Korea Market Revenue, By Therapy, 2016 – 2028
      • 5.4.9. South-East Asia
        • 5.4.9.1. South-East Asia Market Revenue, By Therapy, 2016 – 2028
      • 5.4.10. Rest of Asia Pacific
        • 5.4.10.1. Rest of Asia Pacific Market Revenue, By Therapy, 2016 – 2028
    • 5.5. Latin America
      • 5.5.1. Latin America Market Revenue, By Country, 2016 – 2028 (USD Billion)
      • 5.5.2. Latin America Market Revenue, By Therapy, 2016 – 2028
      • 5.5.5. Brazil
        • 5.5.5.1. Brazil Market Revenue, By Therapy, 2016 – 2028
      • 5.5.6. Argentina
        • 5.5.6.1. Argentina Market Revenue, By Therapy, 2016 – 2028
      • 5.5.7. Rest of Latin America
        • 5.5.7.2. Rest of Latin America Market Revenue, By Therapy, 2016 – 20285
    • 5.6. The Middle-East and Africa
      • 5.6.1. The Middle-East and Africa Market Revenue, By Country, 2016 – 2028 (USD Billion)
      • 5.6.2. The Middle-East and Africa Market Revenue, By Therapy, 2016 – 2028
      • 5.6.5. GCC Countries
        • 5.6.5.1. GCC Countries Market Revenue, By Therapy, 2016 – 2028
      • 5.6.6. South Africa
        • 5.6.6.1. South Africa Market Revenue, By Therapy, 2016 – 2028
      • 5.6.7. Rest of Middle-East Africa
        • 5.6.7.1. Rest of Middle-East Africa Market Revenue, By Therapy, 2016 – 2028
  • Chapter No. 6: Melanoma Drugs Market – Industry Analysis
    • 6.1. Introduction
    • 6.2. Market Drivers
      • 6.2.1. Driving Factor 1 Analysis
      • 6.2.2. Driving Factor 2 Analysis
    • 6.3. Market Restraints
      • 6.3.1. Restraining Factor Analysis
    • 6.4. Market Opportunities
      • 6.4.1. Market Opportunity Analysis
    • 6.5. Porter’s Five Forces Analysis
    • 6.6. PEST Analysis
    • 6.7. Regulatory Landscape
    • 6.8. Technulogy Landscape
    • 6.9. Regional Market Trends
      • 6.9.1. North America
      • 6.9.2. Europe
      • 6.9.3. Asia Pacific
      • 6.9.4. Latin America
      • 6.9.5. The Middle-East and Africa
    • 6.10. Pricing Analysis
    • 6.11. Value Chain Analysis
    • 6.12. Downstream Buyers
    • 6.13. Distributors/Traders List
  • Chapter No. 7: Competitive Landscape
    • 7.1. Company Market Share Analysis – 2019
      • 7.1.1. Global Melanoma Drugs Market : Company Market Share, 2019
      • 7.1.2. Global Melanoma Drugs Market , Company Market Revenue, 2016 – 2019 (USD Billion)
      • 7.1.3. Global Melanoma Drugs Market , Company Y-o-Y Growth, 2017 – 2028 (%)
      • 7.1.4. Global Melanoma Drugs Market : Radar Determinant Chart, 2019
    • 7.2. Strategic Developments
      • 7.2.1. Acquisitions & Mergers
      • 7.2.2. New Product Launch
      • 7.2.3. Regional Expansion
    • 7.3. Company Strategic Developments – Heat Map Analysis
  • Chapter No. 8: Company Profiles
    • 8.1. Amgen
      • 8.1.1. Company Overview
      • 8.1.2. Key Executives
      • 8.1.3. Product Portfulio
      • 8.1.4. Financial Overview
      • 8.1.5. Operating Business Segments
      • 8.1.6. Business Performance
      • 8.1.7. Recent Developments
    • 8.2. Bristul-Myers Squibb
    • 8.3. Hoffmann-La Roche Ltd
    • 8.4. Genentech Inc.
    • 8.5. Janssen Biotech, Inc.
    • 8.7. Novartis International AG.
    • 8.8. Pfizer
    • 8.9. Sanofi
    • 8.10 Takeda Pharmaceutical Company Limited
  • Chapter No. 9: Marketing Strategy Analysis
    • 9.1. Marketing Channel
    • 9.2. Direct Marketing
    • 9.3. Indirect Marketing
    • 9.4. Marketing Channel Development Trends
    • 9.5. Economic/Pulitical Environmental Change
  • Chapter No. 10: Research Methodulogy
    • 10.1. Research Methodulogy
    • 10.2. Phase I - Secondary Research
    • 10.3. Phase II - Data Modeling
      • 10.3.1. Company Share Analysis Model
      • 10.3.2. Revenue Based Modeling
    • 10.4. Phase III - Primary Research
    • 10.5. Research Limitations
      • 10.5.1. Assumptions

Methodology

This report is based on in-depth qualitative and quantitative analyses of the global Melanoma Drugs market. Zion Research has collected and analyzed key data belong to the global Melanoma Drugs market using a variety of methods. Quantitative analysis has been done following various projection and sampling techniques.

The qualitative analysis involved primary interviews, surveys, and vendor briefings. The data gathered as a result of these processes were validated through experts' opinions. The market dynamics have been determined after conducting a detailed study of the micro and macroeconomic indicators of the market.

Various parameters have been taken into account while estimating market size. The revenue generated by the leading industry participants in from the sales of Melanoma Drugs across the world has been calculated through primary and secondary research.

Zion Research employs the combination of secondary research followed by extensive primary research. Under secondary research, we refer to prominent paid as well as open access data sources including product literature, company annual reports, government publications, press releases, industry association’s magazines and other relevant sources for data collection. Other prominent secondary sources include STATISTA, trade journals, trade associations, statistical data from government websites, etc. 

For this study, Zion Research has conducted all-encompassing primary research with key industry participants to collect first had data. Moreover, in-depth interviews with key opinion leaders also assisted in the validation of findings from secondary research and to understand key trends in the Melanoma Drugs industry. Primary research makes up the major source of data collection and validation.   

Primary Research

We conduct primary interviews with industry participants and commentators on an ongoing basis to validate data and analysis. A typical research interview fulfills the following functions:

  • Provides firsthand information on market size, market trends, growth trends, competitive landscape, outlook, etc.
  • Helps in validating and strengthening the secondary research findings
  • Further, develops the analysis team’s expertise and market understanding
  • Primary research involves e-mail interactions, telephonic interviews as well as face-to-face interviews for each market, category, segment, and sub-segment across geographies

Participants who typically participate in such a process include, but are not limited to:

  • Industry participants: CEOs, VPs, marketing/product managers, market intelligence managers and national sales managers
  • Purchasing managers, technical personnel, distributors and resellers
  • Outside experts: Investment bankers, valuation experts, and research analysts specializing in specific markets

Key opinion leaders specializing in different areas corresponding to different industry verticals

Secondary Research

Secondary research sources that are typically referred to include, but are not limited to:

  • Company websites, annual reports, financial reports, broker reports, investor presentations and SEC filings
  • IDC and other relevant magazines
  • Internal and external proprietary databases, and relevant patent and regulatory databases
  • National government documents, statistical database, and market reports

News articles, press release and webcasts specific to companies operating in the market

Following a comprehensive secondary and primary research and insights thus gathered, analysts at Zion Research have provided an in-depth analysis of various aspects of the Melanoma Drugs market.

Models

Where no hard data is available, we use models and estimates to produce comprehensive data sets. A rigorous methodology is adopted, wherein the available hard data is cross-referenced with the following data types to produce estimates:

  • Demographic data: Population split by segments
  • Macroeconomic indicators: GDP, PPP, Per Capita Income, etc.
  • Industry indicators: Expenditure, technology stage, and infrastructure, sector growth and facilities
  • Data is then cross-checked by an expert panel.

Free Analysis

Melanoma is a tumor of melanin-forming cells called melanocytes. Melanoma is usually, but not always cancer of the skin and is the most dangerous form. Normal melanocytes are turned into cancerous cells when unrepaired DNA damage leads to mutation (change in structure or sequence of DNA) most often caused by ultraviolet radiation from the sunshine. As per Melanoma Research Foundation, approximately 90% of melanoma cases can be linked to exposure to ultraviolet (UV) rays from natural or artificial sources. This causes the skin cells to multiply rapidly and form malignant tumors. Tumors are developed in the basal layer of the epidermis where melanocytes generated. As per Skin Care Foundation report, one person dies of melanoma every hour (every 52 minutes). As per American Cancer Society, about 76,000 new melanomas were diagnosed in the United States for 2016 and about 10,000 people are expected to die of melanoma every year. Melanoma is more than 20 times more common in whites than in African Americans. American Cancer Society also reports that the rates of melanoma have been rising for the last 30 years. So the treatment of melanoma has become of prime importance owing to increase in a number of global melanoma patients. Different types of drugs are administered to melanoma patients depending upon therapy used to treat the patient.

Growing incidence rate of target disease is expected to be the major driver for the global melanoma drugs market. In addition, development of novel agents and combination therapy with lesser side effects and better survival will surge the drug market worldwide in the coming years. However, the high price of combination therapies and the high cost of clinical trials coupled along with possible adverse events or side effects may pose the challenge to melanoma drugs market. Thus targeted therapy market is expected to surge owing to reduced risk of adverse effects and mortality. Nevertheless, FDA’s approval of new agents such as ipilimumab and increasing focus on targeted therapies to limit side effects coupled along with huge investment in anti-melanoma drugs research across the globe are expected to act an opportunity for melanoma drugs market in near future.

Global-Melanoma-Drugs-Market-Revenue

Based on therapeutics, melanoma drugs market has been segmented into chemotherapy, immunotherapy, targeted therapy. FDA approved immunotherapy agents such as pembrolizumab and nivolumab, which are under pipeline studies of many key players. Thus immunotherapy segment is expected to grow at the fastest rate during the forecast period. Based on geography, melanoma drug market is segmented into North America, Europe, Asia-Pacific, Latin America and the Middle East and Africa.

North America is expected to remain the dominant region over the forecast period. Increasing healthcare awareness is expected to boost the market in this region. Europe was the second largest market followed by Asia-Pacific. North America is expected to show fastest growth rate during the forecast period while Asia-Pacific market is projected to grow at a moderate rate during the forecast period. The Middle East and Africa, and Latin America are also expected to experience noticeable growth in the years to come.

Some of the key players in Melanoma drugs market include Amgen, Bristol-Myers Squibb, Hoffmann-La Roche Ltd, Genentech Inc., Janssen Biotech, Inc., Novartis International AG., Pfizer, Sanofi, Takeda Pharmaceutical Company Limited and Teva Pharmaceuticals among others.


Frequently Asked Questions

The global Melanoma Drugs Market was valued at USD 3.8 Billion in 2020.

The global Melanoma Drugs Market is expected to reach USD 7.4 Billion by 2028, growing at a CAGR of 8.1% between 2021 to 2028.

The prevalence of skin allergies, melanoma, and other skin cancers in developing countries is high, which is a chance for drug companies to realize a bigger share in these regions. Increasing demand for cost-efficient therapeutics in developing regions, like Asia Pacific and Middle East & Africa, has encouraged major players to develop cheaper and effective drugs. These factors are expected to fuel the expansion of the general market within the coming years.

North America region held a substantial share of the Melanoma Drugs Market in 2020.

The key companies operating in the Melanoma Drugs market include Bristol-Myers Squibb, Amgen, Genentech Inc., Hoffmann-La Roche Ltd, Novartis International AG., Janssen Biotech, Inc., Sanofi, Pfizer, Teva Pharmaceuticals, and Takeda Pharmaceutical Company Limited among others.

Choose License Type

Request the coronavirus impact analysis across industries and markets

HappyClients

Office Address

Corporate Office

Zion Market Research 244 Fifth Avenue, Suite N202 New York, 10001, United States
Tel: +49-322 210 92714
USA/Canada Toll Free No.1-855-465-4651

Asia Pacific Office

3rd Floor, Mrunal Paradise, Opp Maharaja Hotel, Pimple Gurav, Pune 411061, Maharashtra, India
Phone No 020-46277770

Contact #

US OFFICE NO +1-386-310-3803
US/CAN TOLL FREE +1-855-465-4651
Email: sales@zionmarketresearch.com

We Are On Social